Strongest evidence: The most robust research on Vitamin C is for reducing systolic blood pressure, graded as moderate evidence strength. All 3 studies reported beneficial effects (none neutral or harmful), with two meta-analyses showing moderate reductions (~3.7 mmHg on average). The evidence primarily comes from adults, particularly those with type 2 diabetes, though doses and forms were not consistently reported.
Mixed or weaker evidence: For reducing oxidative stress, the evidence is low strength. Of 4 studies, 3 reported beneficial effects (moderate to large) and 1 was neutral. The findings are considered preliminary due to the small evidence base and heterogeneity across studies. The most studied dose was 1000 mg/day, with effects observed at 12 weeks in a clinical trial involving coronary artery disease patients and older women with sarcopenia.
Effective dose patterns: A clear dose pattern is limited, as only one oxidative stress study reported a specific dose (1000 mg/day). For blood pressure, doses were not consistently reported, preventing cross-outcome dose convergence. No effective dose could be derived for blood pressure from the available data.
Population insights: Populations studied are distinct by outcome. Blood pressure research focuses on adults, especially those with type 2 diabetes. Oxidative stress research targets clinical populations, such as patients with coronary artery disease and older women with sarcopenia. No cross-cutting population themes emerge due to the small number of outcomes.
Notable caveats: Both syntheses have small evidence bases (3–4 studies), so conclusions should be considered preliminary. Publication bias is a concern for blood pressure research, as null-result studies are less likely to be published. For oxidative stress, only one study reported a specific dose and duration, limiting extrapolation. Neither synthesis allows for strong generalizations about effectiveness across broader populations.